Current Report Filing (8-k)
March 16 2020 - 4:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): March 10, 2020
ABEONA
THERAPEUTICS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-15771
|
|
83-0221517
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
1330
Avenue of the Americas, 33rd Floor,
New
York, NY 10019
(Address
of principal executive offices) (Zip Code)
(646)
813-4712
(Registrant’s telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.01 par value
|
|
ABEO
|
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02.
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
|
On
March 10, 2020, Christine Berni Silverstein, Chief Financial Officer of Abeona Therapeutics Inc. (the “Company”),
notified the Company of her resignation as Chief Financial Officer effective on March 31, 2020. Ms. Silverstein has agreed to
support the Company and will do so as an advisor during a transitional period between March 31, 2020 and June 30, 2020 (the “Transition
Period”).
On
March 11, 2020, the Board of Directors of the Company (the “Board”) elected Ms. Silverstein to serve as a Class
1 director of the Company until the 2020 annual meeting of stockholders and until her successor is duly elected and qualified.
Ms.
Silverstein will receive non-employee director compensation under the standard arrangements and agreements described in the Company’s
2019 Annual Meeting Proxy Statement, including cash compensation and equity awards. There are no arrangements or understandings
between Ms. Silverstein and any other person pursuant to which Ms. Silverstein was selected as a director.
Pursuant
to a letter agreement dated March 13, 2020 (the “Agreement”), Ms. Silverstein has agreed to reasonably assist with
transition duties as may be reasonably requested by the Company for the Transition Period. In accordance with the Agreement, Ms.
Silverstein will continue to receive her annual base salary during the Transition Period, a prorated portion of her target bonus
for 2020, and a lump-sum payment equal to COBRA premiums that Ms. Silverstein would pay if she elected continued health coverage
under the Company’s health plan. In consideration of her services with the Company through the Transition Period and her
eligibility to receive payment for the transition duties, Ms. Silverstein has agreed to waive all claims available under federal,
state or local law against the Company and the directors, officers, employees, employee benefit plans and agents of the Company
arising out of employment with the Company.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Abeona
Therapeutics Inc.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/
Edward Carr
|
|
|
Name:
Edward Carr
|
|
|
Title: Chief
Accounting Officer
|
Date:
March 16, 2020
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abeona Therapeutics (NASDAQ:ABEO)
Historical Stock Chart
From Apr 2023 to Apr 2024